A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

Summary

The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease. The expected trial duration per participant is approximately 86 weeks.

Timeline

Start

2025-03-31

Primary completion

2026-09-15

Completion

2027-09-14

Drugs

Indications